Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.

For 10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.

If you have metastatic bladder cancer, you may also be at higher risk for kidney problems, including acute kidney injuries ...

Discover a comprehensive palliative care plan designed to enhance quality of life for those with metastatic bladder cancer.

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

In about 5–10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the treatment of bladder cancer. The PD-1/antibody-drug conjugate pairing ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the disease.The ongoing SunRISe-3 trial (NCT05714202) is testing TAR-200 head-to-head ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitters ...